Lv2
172 积分 2023-06-24 加入
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
11天前
已完结
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)
13天前
已完结
Use of Structural Alerts for Reactive Metabolites in the Application SpotRM
23天前
已完结
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury
24天前
已完结
Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health
24天前
已关闭
ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence
26天前
已完结
Reaction phenotyping to assess victim drug-drug interaction risks
26天前
已完结
Drug–drug interactions and their implications on the pharmacokinetics of the drugs
26天前
已完结
Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models
26天前
已关闭
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
26天前
已完结
皖公网安备34019202002308
